Literature DB >> 19838213

RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1.

C A Reed1, C N Mayhew, A K McClendon, X Yang, A Witkiewicz, E S Knudsen.   

Abstract

Hepatocellular carcinoma (HCC) is a significant worldwide health concern that is associated with discrete etiological events, encompassing viral infection, metabolic stress and genotoxic compounds. In particular, exposure to the genotoxic hepatocarcinogen aflatoxin B1 (AFB1) is a significant factor in the genesis of human liver cancer. Presumably, genetic events associated with HCC could influence the effect of environmental insults, yielding a predilection for tumor development. The retinoblastoma (RB) tumor suppressor pathway is functionally inactivated in HCC through discrete mechanisms; however, the role of RB in suppressing tumorigenesis in this disease is poorly understood. Therefore, we analysed how RB status affects the response to AFB1 in reference to acute exposures and tumor development reflective of chronic exposure. Liver-specific Rb deletion resulted in an aberrant proliferative response to AFB1. This cell-cycle induction was associated with increased levels of secondary genetic damage and failure in appropriate cell-cycle coupling. This effect of RB loss was unique to AFB1 and involved the induction of a non-canonical proliferative pathway, and was not merely reflective of the overall cell-cycle deregulation or aberrant regenerative responses. The acute responses to AFB1 exposure presaged aberrations in hepatocyte nuclear morphology and ploidy with RB loss. Correspondingly, RB-deficient livers showed significantly enhanced susceptibility to liver tumorigenesis initiated by AFB1. Combined, these studies show that RB has a critical role in mediating checkpoint responses in liver tissue to maintain genome integrity and in suppressing tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19838213      PMCID: PMC2978420          DOI: 10.1038/onc.2009.303

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Genetic alterations in hepatocellular adenomas.

Authors:  Paulette Bioulac-Sage; Pierre Laurent-Puig; Charles Balabaud; Jessica Zucman-Rossi
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

2.  Molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Snorri S Thorgeirsson; Joe W Grisham
Journal:  Nat Genet       Date:  2002-08       Impact factor: 38.330

Review 3.  Environmental factors and risk for hepatocellular carcinoma.

Authors:  Mimi C Yu; Jian-Min Yuan
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

4.  RB-dependent S-phase response to DNA damage.

Authors:  K E Knudsen; D Booth; S Naderi; Z Sever-Chroneos; A F Fribourg; I C Hunton; J R Feramisco; J Y Wang; E S Knudsen
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.

Authors:  Yoshihiro Edamoto; Akira Hara; Wojciech Biernat; Luigi Terracciano; Gieri Cathomas; Hans-Martin Riehle; Masanori Matsuda; Hideki Fujii; Jean-Yves Scoazec; Hiroko Ohgaki
Journal:  Int J Cancer       Date:  2003-09-01       Impact factor: 7.396

Review 6.  Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer.

Authors:  David R McGivern; Stanley M Lemon
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

7.  Reduced hepatocyte proliferation is the basis of retarded liver tumor progression and liver regeneration in mice lacking N-acetylglucosaminyltransferase III.

Authors:  Xiaoping Yang; Jian Tang; Charles E Rogler; Pamela Stanley
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

8.  Alpha-fetoprotein production by the synchronized regenerating murine liver. Its independence on the phases of the mitotic cycle.

Authors:  M N Lazareva
Journal:  Oncodev Biol Med       Date:  1981

9.  Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma.

Authors:  Y J Zhang; W Jiang; C J Chen; C S Lee; S M Kahn; R M Santella; I B Weinstein
Journal:  Biochem Biophys Res Commun       Date:  1993-10-29       Impact factor: 3.575

Review 10.  A new role for E2F-1 in checkpoint control.

Authors:  Craig Stevens; Nicholas B La Thangue
Journal:  Cell Cycle       Date:  2003 Sep-Oct       Impact factor: 4.534

View more
  13 in total

Review 1.  Endoreplication and polyploidy: insights into development and disease.

Authors:  Donald T Fox; Robert J Duronio
Journal:  Development       Date:  2013-01-01       Impact factor: 6.868

2.  Silencing of survivin by YM155 induces apoptosis and growth arrest in hepatocellular carcinoma cells.

Authors:  Changhe Zhang; Xiaofei Cao; Yongxiang Gei; Yong Wang; Guiyuan Liu; Guochang Cheng; Qinghong Liu
Journal:  Oncol Lett       Date:  2015-07-02       Impact factor: 2.967

3.  Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma.

Authors:  Rong-Dang Fu; Chun-Hui Qiu; Hu-An Chen; Zhi-Gang Zhang; Min-Qiang Lu
Journal:  Tumour Biol       Date:  2014-05-06

4.  CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.

Authors:  A Kathleen McClendon; Jeffry L Dean; Dayana B Rivadeneira; Justine E Yu; Christopher A Reed; Erhe Gao; John L Farber; Thomas Force; Walter J Koch; Erik S Knudsen
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

5.  Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.

Authors:  L Cheng; Z Zhou; A Flesken-Nikitin; I A Toshkov; W Wang; J Camps; T Ried; A Y Nikitin
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

6.  RB tumor suppressive function in response to xenobiotic hepatocarcinogens.

Authors:  Christopher Reed; Jack Hutcheson; Christopher N Mayhew; Agnieszka K Witkiewicz; Erik S Knudsen
Journal:  Am J Pathol       Date:  2014-04-13       Impact factor: 4.307

Review 7.  Newly identified aspects of tumor suppression by RB.

Authors:  Patrick Viatour; Julien Sage
Journal:  Dis Model Mech       Date:  2011-09       Impact factor: 5.758

8.  Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway.

Authors:  Patrick Viatour; Ursula Ehmer; Louis A Saddic; Craig Dorrell; Jesper B Andersen; Chenwei Lin; Anne-Flore Zmoos; Pawel K Mazur; Bethany E Schaffer; Austin Ostermeier; Hannes Vogel; Karl G Sylvester; Snorri S Thorgeirsson; Markus Grompe; Julien Sage
Journal:  J Exp Med       Date:  2011-08-29       Impact factor: 14.307

9.  The retinoblastoma tumor suppressor regulates a xenobiotic detoxification pathway.

Authors:  Maria Teresa Sáenz Robles; Ashley Case; Jean-Leon Chong; Gustavo Leone; James M Pipas
Journal:  PLoS One       Date:  2011-10-12       Impact factor: 3.240

10.  RNA-Seq profiling reveals novel hepatic gene expression pattern in aflatoxin B1 treated rats.

Authors:  B Alex Merrick; Dhiral P Phadke; Scott S Auerbach; Deepak Mav; Suzy M Stiegelmeyer; Ruchir R Shah; Raymond R Tice
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.